Related Experiment Video
Updated: May 25, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
[Antifungal therapy update: new drugs and medical uses]
1Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España. fortunabete@gmail.com
Abstract:
Increases in the rates of fungal infections, as well as their associated morbidity and mortality has led to a need for additional antifungal agents. The most common serious fungal agents in immunosuppressed and critically ill patients are Candida spp. and Aspergillus spp., although other emerging fungi must be considered. Rational, early systemic antifungal treatment should be based on diagnostic imaging techniques and conventional mycological and non-culture-based procedures. While the availability of new therapeutic options is an important advance, antifungal therapy has become increasingly complex. In addition to the available antifungal armamentarium, recent research has resulted in the introduction of three new antifungal agents: micafungin, anidulafungin, and posaconazole. This article provides an update, based on the latest scientific evidence, of the clinical efficacy, pharmacokinetics, safety and dosing of antifungal drugs administered in the management of Candida spp., Aspergillus spp., Cryptococcus spp., Zygomycetes, Scedosporium spp. and Fusarium spp.
Insights
Rising fungal infections necessitate new antifungal drugs. This review updates clinical evidence on new agents like micafungin, anidulafungin, and posaconazole for treating serious Candida and Aspergillus infections.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Increasing rates of invasive fungal infections and associated mortality highlight the urgent need for novel antifungal agents.
- Candida spp. and Aspergillus spp. are primary pathogens in immunocompromised and critically ill patients, but emerging fungi also pose significant threats.
- Antifungal therapy is becoming more complex with the introduction of new agents, requiring updated clinical guidance.
Purpose of the Study:
- To provide an evidence-based update on the clinical efficacy, pharmacokinetics, safety, and dosing of antifungal drugs.
- To review the management of infections caused by Candida spp., Aspergillus spp., Cryptococcus spp., Zygomycetes, Scedosporium spp., and Fusarium spp.
- To discuss the role of newly introduced antifungal agents: micafungin, anidulafungin, and posaconazole.
Main Methods:
- Systematic review of the latest scientific evidence.
- Analysis of clinical trial data and pharmacokinetic studies.
- Evaluation of safety profiles and dosing recommendations for various antifungal drugs.
Main Results:
- Micafungin, anidulafungin, and posaconazole represent significant advances in antifungal armamentarium.
- Updated data on the efficacy and safety of established and novel antifungal agents across a spectrum of fungal pathogens.
- Guidance on rational, early systemic antifungal treatment integrating diagnostic and therapeutic strategies.
Conclusions:
- New antifungal agents offer improved therapeutic options for complex fungal infections.
- Evidence-based management of fungal infections requires continuous updates on drug efficacy, safety, and dosing.
- Optimizing antifungal therapy is crucial for reducing morbidity and mortality in vulnerable patient populations.
Related Concept Videos
Antifungal Agents
Anthelminthic Agents
Endocarditis III: Medical Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Fungal Phylum Microsporidia
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
